Dosage forms comprising a CETP inhibitors and an HMG-CoA reductase inhibitor
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Mar 1, 2011
Grant Date -
Oct 7, 2004
app pub date -
Dec 18, 2003
filing date -
Dec 20, 2002
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
A dosage form comprises (1) a solid amorphous dispersion comprising a cholesterol ester transfer protein inhibitor and an acidic concentration-enhancing polymer and (2) an HMG-CoA reductase inhibitor. The solid amorphous dispersion and the HMG-CoA reductase inhibitor are combined in the dosage form so that the solid amorphous dispersion and the HMG-CoA reductase inhibitor are substantially separate from one another in the dosage form.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully